Goldman Sachs Group Inc Immunovant, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 521,673 shares of IMVT stock, worth $14.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
521,673
Previous 411,918 26.64%
Holding current value
$14.4 Million
Previous $10.9 Million 31.98%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$27.51 - $27.51 $3.02 Million - $3.02 Million
109,755 Added 26.64%
521,673 $14.4 Million
Q2 2024

Aug 13, 2024
BUY
$25.1 - $31.61 $1.57 Million - $1.98 Million
62,741 Added 17.97%
411,918 $10.9 Million
Q1 2024

May 15, 2024
SELL
$30.27 - $43.79 $3.3 Million - $4.77 Million
-108,954 Reduced 23.78%
349,177 $11.3 Million
Q4 2023

Feb 13, 2024
SELL
$31.31 - $44.19 $1.64 Million - $2.31 Million
-52,309 Reduced 10.25%
458,131 $19.3 Million
Q3 2023

May 14, 2024
BUY
$18.55 - $39.96 $970,331 - $2.09 Million
52,309 Added 11.42%
510,440 $19.6 Million
Q3 2023

Nov 14, 2023
BUY
$18.55 - $39.96 $3.44 Million - $7.4 Million
185,194 Added 56.94%
510,440 $19.6 Million
Q2 2023

May 14, 2024
SELL
$14.2 - $23.75 $1.64 Million - $2.75 Million
-115,612 Reduced 26.22%
325,246 $6.17 Million
Q2 2023

Aug 14, 2023
SELL
$14.2 - $23.75 $1.64 Million - $2.75 Million
-115,612 Reduced 26.22%
325,246 $6.17 Million
Q1 2023

May 14, 2024
BUY
$15.27 - $19.72 $1.06 Million - $1.37 Million
69,610 Added 18.75%
440,858 $6.84 Million
Q1 2023

May 11, 2023
BUY
$15.27 - $19.72 $1.06 Million - $1.37 Million
69,610 Added 18.75%
440,858 $6.84 Million
Q4 2022

May 14, 2024
BUY
$6.59 - $17.75 $1.98 Million - $5.33 Million
300,179 Added 422.38%
371,248 $6.59 Million
Q4 2022

Feb 13, 2023
BUY
$6.59 - $17.75 $1.98 Million - $5.33 Million
300,179 Added 422.38%
371,248 $6.59 Million
Q3 2022

May 14, 2024
SELL
$3.93 - $6.37 $683,360 - $1.11 Million
-173,883 Reduced 70.99%
71,069 $396,000
Q3 2022

Nov 10, 2022
SELL
$3.93 - $6.37 $683,360 - $1.11 Million
-173,883 Reduced 70.99%
71,069 $396,000
Q2 2022

May 14, 2024
SELL
$3.38 - $5.65 $720,545 - $1.2 Million
-213,179 Reduced 46.53%
244,952 $955,000
Q2 2022

Aug 15, 2022
SELL
$3.38 - $5.65 $374,307 - $625,692
-110,742 Reduced 31.13%
244,952 $955,000
Q1 2022

May 16, 2022
BUY
$5.06 - $8.77 $312,935 - $542,380
61,845 Added 21.05%
355,694 $1.96 Million
Q4 2021

Feb 14, 2022
SELL
$7.33 - $9.32 $1.21 Million - $1.54 Million
-165,124 Reduced 35.98%
293,849 $2.5 Million
Q3 2021

Nov 10, 2021
BUY
$7.01 - $11.37 $3.22 Million - $5.22 Million
458,973 New
458,973 $3.99 Million

Others Institutions Holding IMVT

# of Institutions
211
Shares Held
66.9M
Call Options Held
2.3M
Put Options Held
631K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email